Lobar Hepatocellular Carcinoma with Ipsilateral Portal Vein Tumor Thrombosis Treated with Yttrium-90 Glass Microsphere Radioembolization: Preliminary Results

摘要: Portal vein tumor thrombosis (PVTT) is a common complication of hepatocellular carcinoma (HCC) and has negative impact on prognosis. This characteristic feature led to the rationale present trial designed assess efficacy safety yttrium-90 glass-microsphere treatment for advanced-stage lobar HCC with ipsilateral PVTT. 18 patients unresectable PVTT were treated in our institution (90)Y-microS radioembolization. Patients evaluated every 3 6 months response, survival, toxicity. Mean follow-up was 13.0 (2.2-50.6). Outcomes were: complete response (n = 2), partial 13), stable disease 1), progressive 2) giving control rate 88.9%. Four downstaged. Treating portal radioembolization safe efficacious. Further clinical trials are warranted confirm these results compare sorafenib, taking into account not only survival but also possibility secondary surgery putative curative intention after downstaging.